Coagulo has developed the world’s first testing system that can detect, identify and quantify the effect of all currently-prescribed anticoagulants.

There are currently >10 million people on anticoagulants in the U.S. and anticoagulants are the #1 cause of drug-related adverse events and related hospitalizations. Oral anticoagulants are commonly prescribed for atrial fibrillation, autoimmune disease, infections, various cancers and after trauma or surgery.

Direct Oral Anticoagulants (DOACs) are a new class of blockbuster drugs that account for >50% of all oral anticoagulant prescriptions, but for which there is currently no FDA-approved test. Current coagulation testing is based on tests developed more than 50 years ago that provide only general and very limited information on the cause of coagulation abnormalities. This puts patients at unnecessary risk of adverse bleeding events, especially in the emergency and surgical settings.

Coagulo’s platform detects, identifies and quantifies the effect of all anticoagulants in whole blood and communicates actionable results to healthcare providers in under 10 minutes. In a 100-patient blinded clinical study performed at the MGH Emergency Department, Coagulo demonstrated that its test identified patients on DOACs with 100% specificity and over 95% sensitivity. Coagulo’s technology works with all direct and indirect Factor IIa and Xa inhibitors, including DOACs, and can also be used to detect the reversal of anticoagulation via the administration of bypassing agents or specific antidotes.